Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 safety study of CIM101 in the patients with metastatic lung cancer who are eligible for treatment with a check point inhibitor

Next Previous
X
Search
Trial Profile

A phase 1 safety study of CIM101 in the patients with metastatic lung cancer who are eligible for treatment with a check point inhibitor

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CIM 101 (Primary)
  • Indications Lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Jan 2021 According to a CiMaas media release, company has received an important stimulus from the Netherlands for this trial.It concerns a loan of 2.4 million euro.
    • 09 Jan 2021 According to a CiMaas media release, Dr. Lizza Hendriks, pulmonologist at MUMC +, Maastricht, and her colleague Dr. Berber Piet, pulmonologist at the Radboud University Nijmegen Medical Center, Nijmegen are the investigators for this trial.
    • 02 Nov 2019 According to a CiMaas media release, this trial is expected to start in 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top